Recordati Industria Chimica e Farmaceutica SpA

IT

RECI

Health Care

13.155 ₽

Current price

Sell
13.155 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    469 / 1328

  • Position in country

    312 / 520

  • Return on Assets, %

    9.4

    -2.7

  • Debt to Equity, %

    107.2

    19.2

  • Intangible assets and goodwill, %

    64.5

    3.6

  • Revenue CAGR 3Y, %

    12.8

    8.5

  • Total Equity change 1Y, %

    12.4

    0

  • Revenue Y, % chg

    16

    0.5

  • P/E

    26.2

    22.7

  • P/BV

    6

    1.5

  • P/S

    4.9

    2.3

  • EV/S

    5.7

    2.4

  • EV/EBITDA

    16.6

    7.4

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    321

    51.3

  • Forward P/E

    19.6

    15.6

  • Dividend Yield, %

    2.4

    1.7

  • Forward Dividend Yield, %

    11.7

    0.2

  • Expected dividend per share

    1.5

    0

  • Dividend Ex Date

    2024-05-20

Get an analytical review of this company

Competitors

Ranks

  • Novo Nordisk A/S

    00%

  • Sanofi SA

    00%

  • AstraZeneca PLC

    00%

  • Recordati Industria Chimica e Farmaceutica SpA

    00%

  • Eli Lilly and Co

    00%

  • Roche Holding AG

    00%

  • Novartis AG

    00%

  • Johnson & Johnson

    00%

  • Merck & Co Inc

    00%

  • Pfizer Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Italy

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Pharmaceuticals

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    11083.1

  • Ticker

    RICFY.PK

  • ISIN

    US75625L1008

  • IPO date

    1984-01-01

  • Availability on Russian exchanges

    No

  • Reporting for

  • Date fact. publication of reports

Company Description

Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.